Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Undersøgelse for at evaluere effektiviteten af ​​et probiotikum til lindring af infantil koliksymptomer (PIXAR)

22. september 2026 opdateret af: The Archer-Daniels-Midland Company

En randomiseret, dobbeltblindet, placebo-kontrolleret undersøgelse for at evaluere effektiviteten af ​​et probiotikum til lindring af infantile koliksymptomer

This study evaluates the efficacy of single strain probiotic administered in a form of a sachet in the treatment of infant colic in infants 3-12 weeks old.

Studieoversigt

Status

Afsluttet

Betingelser

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

101

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
        • Atlantia Food Clinical Trials
    • Maharashtra
      • Pune, Maharashtra, Indien, Pune 411 041
        • Pulse Multispeciality Hospital,

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

3 uger til 2 måneder (Barn)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Gestational age of minimum 37 weeks.
  • Birthweight of minimum 2500 g (5.5 lb.).
  • Age of greater than 3 weeks and less than 12 weeks at enrolment.
  • Confirmed Infantile colic defined as: parental report of crying and/or fussing ≥3 hours/day for ≥3 days/week, confirmed prior to enrolment with an infant behaviour diary recording >3 hours of crying in a 24-hour period (eDiary App completed daily during run-in period & for duration of study).
  • Participant Informed Consent form signed by parent or legal guardian.
  • Infant is considered healthy following physical exam.
  • Parents/Caregivers are willing to comply with the trial procedures, and the mother of the infant can attend all three trial visits

Exclusion Criteria:

  • Use of antibiotics by the infant within 2-weeks prior to the screening visit or during the run-in period of the trial.
  • Use of probiotic supplements from child's birth to enrolment (this includes infant formulas containing probiotics).
  • Need for hospitalization (defined as readmission to a hospital ward after initial discharge following delivery).
  • Congenital disorders that, in the opinion of the investigator, would impact the gastrointestinal tract.
  • Failure to thrive.
  • Known lactose or gluten intolerance.
  • Known allergy to cow's milk proteins, fish, or any of the substances of the trial product or placebo.
  • Known other causes for abdominal pain (e.g., pyloric stenosis).
  • Participation in any other interventional clinical study.
  • Immuno-compromised participant or participant with other severe chronic disorder.
  • Use of probiotic supplements by breastfeeding mother from child's birth to enrolment.
  • Use of antibiotics by breastfeeding mother within 2-weeks prior to the screening visit or during the run-in period of the trial.
  • Any Participant/Parent/Caregiver who is an employee of the investigational site or an Atlantia Clinical Trials employee or their close family member or a member of their household.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Active

Arm receiving investigation product (probiotic)

Single strain probiotic in a form of a sachets with a daily dose of 1.0E+9 Colony Forming Unit (CFU) per day for 4 weeks

Placebo komparator: Placebo

Arm receiving placebo

Placebo

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in cry and fuss time
Tidsramme: Day 0, Day 28

eDiary parent reported cry and fuss time

Day 0, Day 28

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in cry and fuss time
Tidsramme: Day 0, Day 7

eDiary parent reported cry and fuss time

Day 0, Day 7
Resolution of colic symptoms
Tidsramme: Day 0, Day 28

Reduction of cry and fuss time (parent reported) greater than 90% comparing to baseline

Day 0, Day 28
Change in cry and fuss time bouts
Tidsramme: Day 0, Day 7, Day 28

eDiary parent reported cry and fuss bouts

Day 0, Day 7, Day 28
Change in sleeping time
Tidsramme: Day 0, Day 7, Day 28

eDiary parent reported sleep time

Day 0, Day 7, Day 28
Change in the use of rescue medications
Tidsramme: Day 0, Day 28

Change in the proportion of participants needing to use rescue medications between the study arms

Day 0, Day 28

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in maternal quality of life and mental health
Tidsramme: Day 0, Day 28

Change in maternal QoL using WHO QOL/BREF (improvement marked by increase in the total score)

Day 0, Day 28
Change in maternal quality of life and mental health
Tidsramme: Day 0, Day 28

Change in maternal QoL using MAPP/QoL (improvement marked by increase in the total score)

Day 0, Day 28
Resolution of colic symptoms
Tidsramme: Day 0, Day 28

Reduction of cry and fuss time (parent reported) greater than 50% comparing to baseline

Day 0, Day 28
Change in the use of rescue medication drops
Tidsramme: Day 0, Day 7, Day 28

Change in the number of rescue medication drops used between the study arms

Day 0, Day 7, Day 28
Change in duration of daily crying and fussing episodes
Tidsramme: Day 0, Day 7, Day 28

Change in mean duration per crying and fussing episode per day

Day 0, Day 7, Day 28
Changes in gut microbiome composition
Tidsramme: Day 0, Day 28

Changes in microbiome composition as measured by changes in alpha and beta diversity of the gut microbiome throughout the study as compared to placebo and baseline

Day 0, Day 28
Change in fecal calprotectin concentration
Tidsramme: Day 0, Day 28

Changes in fecal calprotectin concentration throughout the study as compared to placebo and baseline

Day 0, Day 28
Adverse Events (AEs)
Tidsramme: From enrolment to Day 35

Reports of Adverse Events (AEs) and Serious Adverse Events (SAEs)

From enrolment to Day 35
Change in vital signs
Tidsramme: Day 0, Day 28

Changes in vital sign measurements (heart rate [bpm] and body temperature [°F]) collected during the study will be summarised by treatment group

Day 0, Day 28

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

30. september 2022

Primær færdiggørelse (Faktiske)

15. april 2026

Studieafslutning (Faktiske)

15. april 2026

Datoer for studieregistrering

Først indsendt

21. juni 2022

Først indsendt, der opfyldte QC-kriterier

21. juni 2022

Først opslået (Faktiske)

27. juni 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

25. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner